We are developing baxdrostat (CIN-107) for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology. To support the advancement of this “pipeline-in-a-product” opportunity, we are currently conducting Phase 2 clinical trials of baxdrostat (CIN-107) in hypertension, hypertension in CKD, and primary aldosteronism.

Hypertension

Preclinical
Phase 1
Phase 2
Phase 3
brightn
  • Treatment-Resistant Hypertension is defined as a high blood pressure that does not respond well to aggressive medical treatment.
  • Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CIN-107 as Compared to Placebo After 12 Weeks of Treatment in Patients With Treatment-Resistant Hypertension (ClinicalTrials.gov ID: NCT04519658)
  • Study Enrollment Completed
Halo logo
  • Uncontrolled Hypertension is defined as high blood pressure that is inadequately treated.
  • A Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Dose Strengths of CIN-107 as Compared to Placebo After 8 Weeks of Treatment in Patients With Uncontrolled Hypertension (ClinicalTrials.gov ID: NCT05137002)
  • HALO Study will be followed by a long-term extension study (OLE) to investigate the safety of CIN-107 over one year of treatment.
  • Study Enrollment Complete
 
  • An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 (HALO) to Evaluate the Long-Term Safety and Effectiveness of CIN-107 (ClinicalTrials.gov ID: NCT05459688)
  • Study Enrolling
CKD
  • Chronic kidney disease (CKD) is defined by a gradual loss of kidney function, which can ultimately lead to kidney failure if left untreated. CKD and hypertension are often associated : declines in kidney function are typically associated with rises in blood pressure, and elevated blood pressure hastens the progression of kidney function decline. Besides its effects on blood pressure, too much aldosterone also has detrimental effects on kidney function through additional mode of actions.
  • A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease (ClinicalTrials.gov ID: NCT05432167)
  • Study Enrolling

Primary Aldosteronism

Preclinical
Phase 1
Phase 2
Phase 3
Spark logo
  • Primary aldosteronism is a condition that occurs when the adrenal glands, two small glands located on the top of the kidneys, produce too much of aldosterone.
  • A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary Aldosteronism (ClinicalTrials.gov ID: NCT04605549)
  • Study Enrolling